Report cover image

Central Nervous System Therapeutics Market by Diseases (Cancer, Degenerative Diseases, Infectious Diseases), Drug Class (Analgesics, Anesthetics, Anti-Epileptics), End-Users - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 185 Pages
SKU # IRE18437004

Description

Central Nervous System Therapeutics Market by Diseases (Cancer, Degenerative Diseases, Infectious Diseases), Drug Class (Analgesics, Anesthetics, Anti-Epileptics), End-Users - Global Forecast 2024-2030


The Central Nervous System Therapeutics Market size was estimated at USD 70.17 billion in 2023 and expected to reach USD 76.41 billion in 2024, at a CAGR 9.37% to reach USD 131.39 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Central Nervous System Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Central Nervous System Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AC Immune SA, Alkermes PLC, AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Private Limited, Lupin Limited, Merck KGaA, Novartis AG, Otsuka Pharmaceutical Co. Ltd, Pfizer, Inc., Shire PLC, Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and Wren Therapeutics Limited.

Market Segmentation & Coverage


This research report categorizes the Central Nervous System Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Diseases
Cancer
Degenerative Diseases
Alzheimer's Disease

Amyotrophic Lateral Sclerosis

Multiple Sclerosis

Parkinson's Disease
Infectious Diseases
Mental Health
Anxiety Disorders

Epilepsy

Psychotic Disorders
Neurovascular Diseases
Trauma
Drug Class
Analgesics
Anesthetics
Anti-Epileptics
Anti-Parkinson Drugs
Antidepressant
CNS stimulants
End-Users
Hospitals
Specialty Clinics
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Central Nervous System Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Central Nervous System Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Central Nervous System Therapeutics Market?
4. What is the market share of the leading vendors in the Central Nervous System Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Central Nervous System Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

185 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Central Nervous System Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of CNS disorders globally
5.1.1.2. Increasing approval of generic products due to patent expiration of key products
5.1.1.3. Increasing government fundings to improve healthcare infrastructure
5.1.2. Restraints
5.1.2.1. High cost of treatments
5.1.3. Opportunities
5.1.3.1. Advancements in diagnostics and therapeutics of CNS diseases
5.1.3.2. Ongoing R&D in pharmaceutical companies
5.1.4. Challenges
5.1.4.1. Strict & extended drug approval procedures
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Central Nervous System Therapeutics Market, by Diseases
6.1. Introduction
6.2. Cancer
6.3. Degenerative Diseases
6.4.1. Alzheimer's Disease
6.4.2. Amyotrophic Lateral Sclerosis
6.4.3. Multiple Sclerosis
6.4.4. Parkinson's Disease
6.4. Infectious Diseases
6.5. Mental Health
6.6.1. Anxiety Disorders
6.6.2. Epilepsy
6.6.3. Psychotic Disorders
6.6. Neurovascular Diseases
6.7. Trauma
7. Central Nervous System Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Analgesics
7.3. Anesthetics
7.4. Anti-Epileptics
7.5. Anti-Parkinson Drugs
7.6. Antidepressant
7.7. CNS stimulants
8. Central Nervous System Therapeutics Market, by End-Users
8.1. Introduction
8.2. Hospitals
8.3. Specialty Clinics
9. Americas Central Nervous System Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Central Nervous System Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Central Nervous System Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AC Immune SA
13.1.2. Alkermes PLC
13.1.3. AstraZeneca PLC
13.1.4. Biogen Inc.
13.1.5. Bristol-Myers Squibb Company
13.1.6. Eisai Co. Ltd.
13.1.7. Eli Lilly and Company
13.1.8. F. Hoffmann-La Roche AG
13.1.9. GlaxoSmithKline PLC
13.1.10. H. Lundbeck A/S
13.1.11. Johnson & Johnson Private Limited
13.1.12. Lupin Limited
13.1.13. Merck KGaA
13.1.14. Novartis AG
13.1.15. Otsuka Pharmaceutical Co. Ltd
13.1.16. Pfizer, Inc.
13.1.17. Shire PLC
13.1.18. Takeda Pharmaceutical Company Limited
13.1.19. TauRx Pharmaceuticals Ltd
13.1.20. Teva Pharmaceutical Industries Ltd.
13.1.21. Wren Therapeutics Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET DYNAMICS
FIGURE 7. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2023 VS 2030 (%)
FIGURE 8. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 12. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us